Should you buy McKesson stock now?
Yes, the technical signal for McKesson is currently BUY. McKesson trades at $842.34 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 18.369 with falling momentum (signal: 18.603); RSI is at 61.8 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $947.13 points to 12.4% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for McKesson stock?
The average analyst price target for McKesson is $947.13. The current price is $842.34, which gives an upside of 12.4%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $852.42 and $1,041.84.
Is McKesson a dividend stock?
Yes, McKesson is a dividend stock with a dividend yield of 0.38%. The latest dividend was $0.94 per share. The latest ex-dividend date (traded without the dividend) was 9/1/2026. The payout ratio is 11.0%, which is considered sustainable. The next dividend payment is scheduled for 10/1/2026.
When does McKesson pay a dividend in 2026?
McKesson pays its next dividend on 10/1/2026. The latest dividend was $0.94 per share with an ex-dividend date of 9/1/2026. The dividend yield is 0.38%. The payout ratio of 11.0% points to a sustainable dividend with room to grow.
What is the risk of McKesson stock?
McKesson is rated as a stock with moderately low risk. the annual standard deviation is 31.3%, which classifies the stock as moderately low risk.
Is McKesson overvalued?
No, McKesson is considered undervalued based on the analyst price target (12.4% upside). McKesson has the following valuation ratios: a P/E ratio of 21.6 (moderately to highly valued), a P/S ratio of 0.2, a P/B ratio of 5.0. The analyst price target suggests that the stock is undervalued by 12.4%.
Is McKesson overbought?
No, McKesson is not overbought. RSI is at 61.8 (neutral zone). The technical indicators show: RSI is at 61.8 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 0.8% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next McKesson earnings report?
The date of the next earnings report for McKesson has not been published yet. Check the company's investor calendar for updates.
Is McKesson shorted?
Yes, McKesson is shorted with 3.3% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying McKesson stock?
No, insiders are not buying McKesson shares – they are net sellers. Over the last 3 months, insiders have made 3 purchases and 17 sales. On a net basis, 32,346,946 $ worth of shares were sold. Across the last 20 reported transactions, the split is 3 purchases and 17 sales, with a net 32,346,946 $ sold. Active sellers include TYLER BRIAN S., Rutledge Napoleon B JR, Rodgers Thomas L and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is McKesson a good stock?
Based on our total score, McKesson is rated as a mediocre stock with a total score of 58 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 68/100, Quality: 38/100, Momentum: 68/100. In addition: analysts see 12.4% upside to the price target; a dividend of 0.38%; technical signal: Buy. Whether McKesson is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for McKesson stock?
The outlook for McKesson based on current data: the average analyst price target is $947.13 (+12.4%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 21.6 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is McKesson stock moving?
McKesson is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can McKesson go?
The average analyst price target for McKesson is $947.13, which corresponds to a potential gain of 12.4% from the current price of $842.34. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can McKesson fall?
We lack enough history to give a specific floor for McKesson. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does McKesson do?
McKesson Corporation driver en stor forretning med sundhedsydelser i USA og internationalt. De tjener primært penge på at distribuere lægemidler og medicinsk udstyr. Deres U.S. Pharmaceutical-division sælger både mærkevarer, generisk medicin og specialpræparater.
McKesson hjæ... The company belongs to the Sundhed sector, more specifically the Medicinsalg industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate McKesson as an investment.
Did McKesson raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from McKesson. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is McKesson making money or losing money?
Yes, McKesson is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 1.2% — which is modest. The operating margin (profit before interest and taxes) is 2.2%. At a P/E ratio of 21.6, you currently pay 21.6 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can McKesson go bankrupt?
The bankruptcy risk of McKesson is rated as elevated. Altman Z2 (a model for assessing financial distress) is 0.85 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does McKesson have a lot of debt?
Yes, McKesson has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
